CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Recruiting

Conditions: Fabry Disease

Interventions: Drug: Pegunigalsidase-alfa

First Posted Date: 2024-10-29

Last Posted Date: 2024-11-18

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 100

Registration Number: NCT06663358

Locations: 🇺🇸
Infusion Associates, Grand Rapids, Michigan, United States

Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

First Posted Date: 2024-06-28

Last Posted Date: 2024-11-14

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 359

Registration Number: NCT06480890

Locations: 🇨🇳
Site 156118 - Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Site 156119 - Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Site 156116 - Beijing Hospital, Beijing, Beijing, China

and more 18 locations

Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF6001 DPI
Drug: Erythromycin

First Posted Date: 2024-05-02

Last Posted Date: 2024-07-03

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 24

Registration Number: NCT06395610

Locations: 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Phase 2

Recruiting

Conditions: Fabry Disease

Interventions: Drug: PRX-102 1 mg/kg every two weeks

First Posted Date: 2024-03-25

Last Posted Date: 2024-12-20

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 22

Registration Number: NCT06328608

Locations: 🇺🇸
Phoenix Children's, Phoenix, Arizona, United States
🇺🇸
Emory Genetics Clinical Trials Center, Atlanta, Georgia, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 9 locations

Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos)

Phase 3

Active, not recruiting

Conditions: Asthma

Interventions: Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a
Drug: Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

First Posted Date: 2024-02-20

Last Posted Date: 2024-12-12

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 837

Registration Number: NCT06264674

Locations: 🇦🇲
Yerevan State Medical University, Heratsi N 1 University Hospital Complex, Yerevan, Armenia
🇦🇲
CITO Medical Center, Yerevan, Armenia
🇦🇲
Armenia Republican Medical Center, Yerevan, Armenia

and more 139 locations

Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3

Recruiting

Conditions: Alpha-Mannosidosis

Interventions: Drug: Velmanase Alfa

First Posted Date: 2023-12-28

Last Posted Date: 2024-11-14

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 5

Registration Number: NCT06184503

Locations: 🇺🇸
Greenwood Genetic Center, Greenwood, South Carolina, United States
🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Phase 1

Recruiting

Conditions: Bronchiectasis

Interventions: Drug: CHF6333
Drug: CHF6333 Placebo

First Posted Date: 2023-12-12

Last Posted Date: 2024-01-22

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 45

Registration Number: NCT06166056

Locations: 🇬🇧
Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection, Cambridge, United Kingdom
🇬🇧
NHS Lothian, Edinburgh, United Kingdom
🇬🇧
The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital, Leeds, United Kingdom

and more 5 locations

Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

Phase 2

Recruiting

Conditions: Uncontrolled Asthma

First Posted Date: 2023-09-08

Last Posted Date: 2024-04-10

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 464

Registration Number: NCT06029595

Locations: 🇦🇷
Site 032027- Centro de Medicina Respiratoria, Argentina, Argentina
🇦🇷
032021 - Centro De Investigaciones Medicas Mar Del Plata, Buenos Aires, Argentina
🇦🇷
Site 032024 -CEMLO- Consultorio Medico CEMLO LOBOS, Buenos Aires, Argentina

and more 192 locations

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Phase 1

Completed

Conditions: Asthma

First Posted Date: 2023-06-12

Last Posted Date: 2024-10-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 69

Registration Number: NCT05898984

Locations: 🇧🇪
SGS Belgium NV - Clinical Pharmacology Unit, Edegem, Antwerpen, Belgium

Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance

Phase 1

Completed

Conditions: Mucociliary Clearance

Interventions: Other: Placebo formulated with HFA-134a propellant via pMDI
Other: Placebo formulated with HFA-152a propellant via pMDI

First Posted Date: 2023-05-25

Last Posted Date: 2024-11-11

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 20

Registration Number: NCT05875025

Locations: 🇬🇧
BDD Pharma - Bio-Imaging Centre, Glasgow, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy